Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03174990 · ClinicalTrials.gov registry record

Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease

A clinical trial, sponsored by University of California, Davis.

Completed
Registry status
195
Enrollment target

NCT03174990: Completed study, sponsored by University of California, Davis.

NCT03174990 is a clinical trial that has completed, run by University of California, Davis. The registered enrollment target is 195 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03174990 has completed, sponsored by University of California, Davis.

COMPLETED
Registry status
195 participants
Enrollment target

Study Summary

This study evaluates the effects of Aspirin and thienopyridine resistance in relation to clinical cardiovascular outcomes as the genetic predictors of, and outcomes associated with aspirin and thienopyridine resistance in patients with peripheral arterial disease (PAD) currently remain unknown.

Primary Outcome

Clopidogrel non-responsiveness was defined as patients with Plavix reaction units (PRU) ≥ 235

Trial Details

FieldValue
Enrollment Target 195 participants
Start Date 2010-08-31
Est. Completion 2013-12-20
University of California, Davis

657 total trials

What the finished NCT03174990 record still lists

NCT03174990 is an observational study that tracks outcomes without assigning an intervention. The registered 195 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT03174990 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT03174990 about?

NCT03174990 is a clinical study titled "Aspirin and Thienopyridine Resistance in Peripheral Arterial Disease". This study evaluates the effects of Aspirin and thienopyridine resistance in relation to clinical cardiovascular outcomes as the genetic predictors of, and outcomes associated with aspirin and thienopyridine resistance in patients with peripheral arterial disease (PAD) currently remain unknown.

What is the current status of trial NCT03174990?

This trial is currently completed. The enrollment target is 195 participants. The study started on 2010-08-31. Estimated completion is 2013-12-20.

Who is sponsoring clinical trial NCT03174990?

This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04276922 · 195 participants · NA

    Creative Arts Program to Reduce Burnout in Healthcare Professionals

  • NCT04829357 · 195 participants

    Post Market Clinical Follow-up Study on TVT ABBREVO® Continence System

  • NCT05054738 · 195 participants · NA

    CRP and S&A for Inpatient Veterans

  • NCT05561595 · 195 participants · NA

    Transdiagnostic Intervention to Reduce Internalized Health-Related Stigma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT03174990, the US trial registry maintained by the National Library of Medicine. NCT03174990 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.